BridgeMD
New treatment option for Brain Metastasis
Official title 18F-FLUC PET/MR in Patients With Brain Mets
ClinicalTrials.gov ID: NCT06159335
What this study is testing
- What it's testing
- The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age 18 years or older
- Able and willing to provide informed consent
- Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
- Received radiation therapy at some point in the last 2 years
- Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which...
You likely can't join if
- Subject unable or unwilling to provide informed consent
- Subject is pregnant
- Subject with contraindication(s) to or inability to undergo a PET/MR or PET/CT
- Known allergy to 18F-Fluciclovine or any of its excipients
See the full eligibility criteria
- Age 18 years or older
- Able and willing to provide informed consent
- Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
- Received radiation therapy at some point in the last 2 years
- Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy...
- Patients are eligible for the study if their most recent standard-of-care MRI, used to assess disease location and extent, raises the question of tumor recurrence versus treatment-related changes. This concern can be...
- Be able to lie still for 30-60 minutes during the imaging procedure
- Willing and able to undergo PET/MRI or PET/CT
- Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are...
- The subject has their own prescription for the medication
- The informed consent process is conducted prior to the self-administration of this medication
- They come to the research visit with a driver
- Subject unable or unwilling to provide informed consent
- Subject is pregnant
- Subject with contraindication(s) to or inability to undergo a PET/MR or PET/CT
- Known allergy to 18F-Fluciclovine or any of its excipients
The study team makes the final eligibility decision.
Where it's taking place
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Madison, Wisconsin, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.